Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Prothena Corporation plcNASDAQ: PRTA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax turns positive

Q1 FY2026 income before tax was $32.72M, compared with -$61.37M a year earlier. Trailing-twelve-month income before tax was -$105.99M.

Context

  • Income before tax amounted to 2073.8% of revenue in FY2025, up 1978.4 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near $32.72M or moves back toward the trailing-twelve-month quarterly average of -$26.5M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$32.72M+251.6% QoQ
Last fiscal yearDec 2025
-$200.83M-55.8% YoY
LTMMar 2026
-$105.99M+8.5% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+153.3%——
1 year-55.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(200.83M) USD
Year-over-year change
-55.8%

Income Before Tax vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.5% is the 4th highest of 10, against a peer median of -6.8%.
  • Income before tax amounts to 182.9% of revenue for PRTA, versus a peer median of 1788.8%.
PRTA Competitors
Income Before Tax for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$856.4M USD-52.4%-26.9%8.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.58M USD+41.2%——
AVXLAnavex Life Sciences Corp.LTM Dec 2025-$39.93M USD+14.3%——
PMNProMIS Neurosciences, Inc.LTM Jun 2026-$42.23M USD-401.1%——
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.2%—1788.8%
PRTAProthena Corporation plcLTM Mar 2026-$105.99M USD+8.5%—182.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$113.28M USD+2.6%——
ANNXAnnexon, Inc.LTM Mar 2026-$196.48M USD-17.4%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$222.34M USD+13.7%——
DNLIDenali Therapeutics Inc.LTM Jun 2026-$511.35M USD-6.8%—14188.4%
Peer median (excluding PRTA) —-6.8%-26.9%1788.8%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.